Literature DB >> 26344706

Use of psychotropic drugs during pregnancy and breast-feeding.

E R Larsen1, P Damkier2, L H Pedersen3, J Fenger-Gron4, R L Mikkelsen5, R E Nielsen6, V J Linde7, H E D Knudsen8, L Skaarup1, P Videbech1.   

Abstract

OBJECTIVE: To write clinical guidelines for the use of psychotropic drugs during pregnancy and breast-feeding for daily practice in psychiatry, obstetrics and paediatrics.
METHOD: As we wanted a guideline with a high degree of consensus among health professionals treating pregnant women with a psychiatric disease, we asked the Danish Psychiatric Society, the Danish Society of Obstetrics and Gynecology, the Danish Paediatric Society and the Danish Society of Clinical Pharmacology to appoint members for the working group. A comprehensive review of the literature was hereafter conducted.
RESULTS: Sertraline and citalopram are first-line treatment among selective serotonin reuptake inhibitor for depression. It is recommended to use lithium for bipolar disorders if an overall assessment finds an indication for mood-stabilizing treatment during pregnancy. Lamotrigine can be used. Valproate and carbamazepin are contraindicated. Olanzapine, risperidone, quetiapine and clozapine can be used for bipolar disorders and schizophrenia.
CONCLUSION: It is important that health professionals treating fertile women with a psychiatric disease discuss whether psychotropic drugs are needed during pregnancy and how it has to be administered.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  breast-feeding; clinical guidelines; pregnancy; psychotropic drugs; recommendations

Mesh:

Substances:

Year:  2015        PMID: 26344706     DOI: 10.1111/acps.12479

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  16 in total

1.  Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques.

Authors:  Sarah R Delaney; Paul R V Malik; Cristiana Stefan; Andrea N Edginton; David A Colantonio; Shinya Ito
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

2.  Patterns and predictors for prescription of psychotropics and mood-stabilizing antiepileptics during pregnancy in Denmark 2000-2016.

Authors:  Per Damkier; Louise Skov Christensen; Anne Broe
Journal:  Br J Clin Pharmacol       Date:  2018-09-17       Impact factor: 4.335

Review 3.  Lithium Use and Non-use for Pregnant and Postpartum Women with Bipolar Disorder.

Authors:  Alison Hermann; Alyson Gorun; Abigail Benudis
Journal:  Curr Psychiatry Rep       Date:  2019-11-07       Impact factor: 5.285

4.  Predictors and Patterns of Psychiatric Treatment Dropout During Pregnancy Among Low-Income Women.

Authors:  Sara L Kornfield; Christina D Kang-Yi; David S Mandell; C Neill Epperson
Journal:  Matern Child Health J       Date:  2018-02

Review 5.  Pharming for Genes in Neurotransmission: Combining Chemical and Genetic Approaches in Caenorhabditis elegans.

Authors:  Stephen M Blazie; Yishi Jin
Journal:  ACS Chem Neurosci       Date:  2018-03-06       Impact factor: 4.418

Review 6.  Does Gender Influence Outcome in Schizophrenia?

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2019-03

7.  Quetiapine Dose Adjustments in Pregnant and Postpartum Women With Bipolar Disorder.

Authors:  Emily A Pinheiro; Katherine L Wisner; Crystal T Clark
Journal:  J Clin Psychopharmacol       Date:  2018-02       Impact factor: 3.153

Review 8.  The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

Authors:  Per Damkier; Poul Videbech
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 9.  Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.

Authors:  Yusuf Cem Kaplan; Omer Demir
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 10.  Effective use of hydroxyurea for sickle cell anemia in low-resource countries.

Authors:  Alexandra Power-Hays; Russell E Ware
Journal:  Curr Opin Hematol       Date:  2020-05       Impact factor: 3.218

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.